Review of recent acetyl-CoA carboxylase inhibitor patents: mid-2007-2008.
BACKGROUND
Acetyl-CoA carboxylase (ACC) is a biologic target that is receiving increased attention for the treatment of obesity and type 2 diabetes mellitus. Inhibition of this enzyme, either in transgenic mice or pharmacologically, has been shown to have beneficial effects on lab animals.


METHODS
This review of the ACC inhibitor patent literature covers the period from mid-2007 to December 2008, during which time a total of 18 patents were published.


CONCLUSIONS
These published patent applications include ACC inhibitors that inhibit the enzyme through modulation of the carboxyltransferase-domain, inhibitors that bind to the biotin carboxylase-domain and novel chemotypes whose mode of action was not disclosed. Furthermore, published patents claim the discovery of ACC2 isoform selective and ACC1/2 non-selective inhibitors.
Corbett
Jeffrey W
JW
Corbett Drug Discovery Partners LLC, 96 South Beechwood Road, Niantic, CT 06357, USA. corbettconsulting@gmail.com
D000103:Acetyl-CoA Carboxylase / Q000037:antagonists & inhibitors*; D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000201:enzymology; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D009765:Obesity / Q000188:drug therapy* / Q000201:enzymology; D010330:Patents as Topic
D004791:Enzyme Inhibitors; D000103:Acetyl-CoA Carboxylase